Research
Hormonal
HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.
Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.
StrongSupportsmedium confidence
HbA1c decreased on average from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks ( p < 0.0001) and to 5.2 ± 0.027 ( p < 0.001) at 24 weeks.
Why this rating
Based on the retrospective cohort study design with a clear outcome measure.
Source
Real‐world observations of using compounded <scp>GLP</scp> ‐1 ± <scp>GIP</scp> agonists within a clinical pharmacist‐managed cardiometabolic clinic
Shannon W. Finks et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2025
cohort · n=50Cited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →